A review of the adverse effects and safety of noradrenergic antidepressants (Q38115737)

29 August 2017

title

A review of the adverse effects and safety of noradrenergic antidepressants (English)

1 reference

29 August 2017

David Taylor

2

0 references

Eromona Whiskey

series ordinal

1

object named as

Eromona Whiskey

1 reference

29 August 2017

language of work or name

English

0 references

publication date

19 June 2013

1 reference

Journal of Psychopharmacology

29 August 2017

published in

1 reference

29 August 2017

volume

27

1 reference

29 August 2017

issue

8

1 reference

29 August 2017

page(s)

732-739

1 reference

Hyponatremia associated with the initiation of reboxetine therapy

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Effects of reboxetine, a selective norepinephrine reuptake inhibitor, on sympathetic and parasympathetic outflow to the heart: preliminary data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

A Review of the Pharmacological and Clinical Profile of Mirtazapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Meta-analysis of suicide-related behavior events in patients treated with atomoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Symposium: Normal and abnormal REM sleep regulation: REM sleep in depression-an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Type of antidepressant therapy and risk of type 2 diabetes in people with depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Mirtazapine in drug-induced excessive sweating

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Antidepressant use and risk of adverse outcomes in older people: population based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Tamsulosin as an effective treatment for reboxetine-associated urinary hesitancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Effects of antidepressants on glucose metabolism and diabetes mellitus type 2 in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Effects of reboxetine on sleep and nocturnal cardiac autonomic activity in patients with dysthymia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Lack of effect of reboxetine on cardiac repolarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

The neural control of micturition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Effect of terazosin on sweating in patients with major depressive disorder receiving sertraline: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Central noradrenergic control of penile erection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Relative mortality from overdose of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Single-agent duloxetine ingestions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

A Review of the Cardiovascular Effects and Toxicity of Tricyclic Antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Successful treatment of reboxetine-induced urinary hesitancy with tamsulosin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Sexual dysfunction, depression, and the impact of antidepressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Cardiovascular Effects of Selective Serotonin Reuptake Inhibitors and Other Novel Antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Reboxetine induces similar sleep-EEG changes like SSRI's in patients with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Antidepressant-induced sweating

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Serotonergic antidepressants associated with an increased risk for hyponatraemia in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Evaluating the effects of an alpha-2 adrenoceptor antagonist on erectile function in the human male. 2. The erectile response to erotic stimuli in men with erectile dysfunction, in relation to age and in comparison with normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Tolerability and safety aspects of mirtazapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Reboxetine: a norepinephrine selective reuptake pump inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Sexual dysfunction and clomipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Seizures and prolonged QTc with atomoxetine overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Hepatic effects of duloxetine-III: analysis of hepatic events using external data sources

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Pharmacological profile of antidepressants and related compounds at human monoamine transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Tricyclic Antidepressant Poisoning

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Prevalence of depression in survivors of acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: scientific basis for overlapping clinical efficacy from a single drug, duloxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Adverse events, toxicity and post-mortem data on duloxetine: case reports and literature survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Urinary Side Effects of Duloxetine in the Treatment of Depression and Stress Urinary Incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Antidepressants and sexual dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

Cardiovascular effects of atomoxetine in children, adolescents, and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/0269881113492027

21 January 2018

Identifiers

DOI

10.1177/0269881113492027

1 reference

29 August 2017

1 reference